Cyclist male holding up his gravel bicycle on the left hand in a victorious gesture.

Factor VIII levels at 42%, 4 days after infusion

Hypothetical patient and scenario

Factor VIII levels at 42%, 4 days after infusion

Hypothetical patient and scenario

A once-weekly Factor VIII replacement therapy with higher-for-longer levels in the near‑normal to normal range (over 40%) for most of the week in adults.

Sign up today to hear from a CoRe manager and receive helpful information about ALTUVIIIO

ALTUVIIIO^® is a first-in-class, once-weekly treatment for hemophilia A

The unique design of ALTUVIIIO combines 3 components that help Factor VIII levels to stay higher in your body for a longer period of time: vWF Fragments; XTEN Technology; and Fc Fusion.

Factor VIII levels in the near-normal to normal range

ALTUVIIIO is a first-in-class Factor VIII replacement therapy that keeps Factor VIII levels in the near-normal to normal range (over 40%) for most of the week and stays above 18% on average in adults—with 1 weekly infusion.^*†

Average trough levels were 18% for adults 18 years and older, 9% for adolescents aged 12 years to under 18 years, 10% for children aged 6 years to under 12 years, and 7% for children aged 1 year to under 6 years.

^†

159 adults and adolescents with severe hemophilia (aged 12 years and older) were enrolled in the XTEND-1 study; 133 people were in Group 1 and switched to ALTUVIIIO prophylaxis from prior prophylaxis therapy. Efficacy of prophylaxis was evaluated in 128 of these patients.

ALTUVIIIO is designed to help Factor VIII stay in the body longer

In a Phase 3 study,* ALTUVIIIO offered a 48-hour half-life, the longest half-life of any Factor VIII replacement therapy. ALTUVIIIO uniquely combines 3 components to help it stay in your body longer. All 3 components work together to keep ALTUVIIIO Factor VIII levels higher for longer.

ALTUVIIIO provides proven bleed protection

In the XTEND-1 study, participants showed significant proven bleed protection when taking ALTUVIIIO as a prophylaxis treatment.

Data from XTEND-1 study shows 0.7 mean bleeds per year (primary outcome).

Data based on treated bleeds.

Once-weekly ALTUVIIIO provides freedom and flexibility

Because ALTUVIIIO has a longer half-life, fewer infusions are needed, providing flexibility and freedom for people with hemophilia A. Infusions are only needed once weekly.